New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
08:35 EDTKERXKeryx Zerenex phase 2 data presentation selected for Kidney Foundation meeting
Keryx Biopharmaceuticals announced that Phase 2 clinical results of Zerenex in non-dialysis dependent chronic kidney disease patients with elevated serum phosphorus and iron deficiency anemia has been selected as a Late Breaking oral presentation at the National Kidney Foundation 2014 Spring Clinical Meeting, taking place April 22-26. This presentation, entitled "Zerenex for the Treatment of Iron-Deficiency Anemia and Reduction of Serum Phosphate in Non-Dialysis Dependent CKD," will be made during the Late Breaking Session on Friday, April 25.
News For KERX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
10:41 EDTKERXOptions with increasing implied volatility
Subscribe for More Information
10:27 EDTKERXOptions with decreasing implied volatility
Subscribe for More Information
July 27, 2015
08:26 EDTKERXKeryx appoints Scott Holmes as CFO
Keryx Biopharmaceuticals announced the appointment of Scott A. Holmes to CFO effective immediately. Holmes will be responsible for Keryx's finance function and will be a member of the company's executive team. He will succeed James Oliviero whose planned departure was announced earlier this year. Oliviero will stay with the company through a transition period. Holmes brings nearly 20 years of life sciences and financial management expertise to Keryx. He joins the company from AMAG Pharmaceuticals where he most recently served as senior vice president, finance and investor relations during a period of high growth driven by acquisitions and public financings. Prior to AMAG, from 2009 to 2011, he was vice president of finance and treasurer of Molecular Biometrics.
July 24, 2015
07:13 EDTKERXKeryx receives CHMP positive opinion for Fexeric
Subscribe for More Information
July 23, 2015
10:00 EDTKERXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:06 EDTKERXKeryx downgraded to Market Perform from Outperform at Cowen
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use